drugset / Trial / NCT01827982
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-54861911 in Healthy Volunteers Compared With Placebo
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of JNJ-54861911 which is currently being developed for the treatment of Alzheimer's Disease.
Timeline
- Start
- 2013-03
- Primary completion
- 2013-07
- Completion
- 2013-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atabecestat | Small molecule | 1 mg | Oral |
| Subject | Atabecestat | Small molecule | 3 mg | Oral |
| Subject | Atabecestat | Small molecule | 9 mg | Oral |
| Subject | Atabecestat | Small molecule | 27 mg | Oral |
| Subject | Atabecestat | Small molecule | 81 mg | Oral |
| Subject | Atabecestat | Small molecule | 160 mg | Oral |
Indications
No indication recorded.